Which statement best describes the norepinephrine and serotonin effects of duloxetine compared with venlafaxine in pain management?

• A. Duloxetine has a more balanced NE/5-HT effect with tolerability differences compared to venlafaxine.
• B. Venlafaxine is primarily a dopamine reuptake inhibitor.
• C. Duloxetine is a pure SSRI.
• D. Venlafaxine reduces NMDA receptor activity.

Answer: (A)

The main idea is how duloxetine and venlafaxine differ in their ability to raise both norepinephrine and serotonin to produce pain relief, and how their tolerability profiles reflect that balance. Duloxetine provides a relatively balanced inhibition of serotonin and norepinephrine reuptake, which supports analgesia via descending pain pathways and tends to come with a tolerability profile shaped by its balanced NE/5-HT activity. Venlafaxine, conversely, is dose-dependent: it acts more like an SSRI at lower doses and increasingly inhibits norepinephrine reuptake at higher doses, which can lead to different or stronger noradrenergic side effects and tolerability differences compared to duloxetine. The other statements aren’t accurate: duloxetine is not a pure SSRI, it’s an SNRI; venlafaxine is not primarily a dopamine reuptake inhibitor; neither drug directly reduces NMDA receptor activity.